Qualitative age interactions in breast cancer studies: A mini-review

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1781-1788

  Jatoi, Ismail ^a   Anderson, William F ^b  

^a University of Texas Health Science Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

age; breast cancer; early onset; interaction; late onset; qualitative

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FENRETINIDE; TAMOXIFEN;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGING; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; EPIDEMIOLOGICAL DATA; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

AGE OF ONSET; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 78650215106     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.139     Document Type: Review

References (48)

1. Anderson WF, Jatoi I, Sherman ME: Qualitative age interactions in breast cancer studies: mind the gap. J. Clin. Oncol. 27, 5308-5311 (2009).
2. Jatoi I, Anderson WF, Rosenberg PS: Qualitative age-interactions in breast cancer: a tale of two diseases? Am. J. Clin. Oncol. 31, 504-506 (2008).
3. Anderson WF, Matsuno R: Breast cancer heterogeneity: a mixture of at least two main types? J. Natl Cancer Inst. 98, 948-951 (2006).
4. Altman DG, Bland JM: Interaction revisited: the difference between two estimates. Br. Med. J. 326, 219 (2003).
5. Jatoi I, Proschan MA: Clinical trial results applied to management of the individual cancer patient. World J. Surg. 30, 1184-1189 (2006).
6. Anderson WF, Chen BE, Brinton LA et al.: Qualitative age interactions (or effect modifcation) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes Control 18, 1187-1198 (2007).
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
8. Maclure M, Schneeweiss S: Causation of bias: the episcope. Epidemiology 12, 114-122 (2001).
9. Bosco JL, Silliman RA, Thwin SS et al.: A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J. Clin. Epidemiol. 63, 64-74 (2010).
10. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl. J. Med. 319, 1681-1692 (1988).
11. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
12. Hutchins LF, Unger JM, Crowley JJ et al.: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
13. Anderson WF, Jatoi I, Devesa SS: Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res. Treat. 90, 127-137 (2005).
14. Clemmesen J: Carcinoma of the breast; results from statistical research. Br. J. Radiol. 21, 583-590 (1948).
15. Jatoi I, Tsimelzon A, Weiss H et al.: Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res. Treat. 89, 173-178 (2005).
16. Chen WY: Exogenous and endogenous hormones and breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22, 573-585 (2008).
17. Hulka BS, Moorman PG: Breast cancer: hormones and other risk factors. Maturitas 61 203-213 (2008).
18. Clavel-Chapelon F, Gerber M: Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res. Treat. 72, 107-115 (2002).
19. Kvale G, Heuch I, Eide GE: A prospective study of reproductive factors and breast cancer. I. Parity. Am. J. Epidemiol. 126, 831-841 (1987).
20. Reeves GK, Pirie K, Green J et al.: Reproductive factors and specifc histological types of breast cancer: prospective study and meta-analysis. Br. J. Cancer 100, 538-544 (2009).
21. Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am. J. Epidemiol. 139, 819-835 (1994).
22. Adami HO, Hansen J, Jung B et al.: Age at frst birth parity and risk of breast cancer in a Swedish population. Br. J. Cancer 42, 651-658 (1980).
23. Lyons TR, Schedin PJ, Borges VF: Pregnancy and breast cancer: when they collide. J. Mammary Gland Biol. Neoplasia 14, 87-98 (2009).
24. Rose DP, Vona-Davis L: Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66, 33-38 (2010).
25. Rothwell PM: Treating individuals 2. Subgroup analysis in randomised controlled trials: importance indications and interpretation. Lancet 365, 176-186 (2005).
26. Jatoi I: Breast cancer screening. Am. J. Surg. 177, 518-524 (1999).
27. Jatoi I, Anderson WF: Cancer screening. Curr. Probl. Surg. 42, 620-682 (2005).
28. Cox B: Variation in the effectiveness of breast screening by year of follow-up. J. Natl Cancer Inst. Monogr. 22, 69-72 (1997).
29. Moss SM, Cuckle H, Evans A et al.: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368, 2053-2060 (2006).
30. Kopans DB: Breast-screening brawl. Science 275, 1721-1724 (1997).
31. Smith RA: The ongoing evaluation of breast cancer screening. Cancer 100, 1327-1330 (2004).
32. de Koning HJ, Boer R, Warmerdam PG et al.: Quantitative interpretation of age-specifc mortality reductions from the Swedish breast cancer-screening trials. J. Natl Cancer Inst. 87, 1217-1223 (1995).
33. Anderson WF, Chen BE, Jatoi I et al.: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res. Treat. 100, 121-126 (2006).
34. Jatoi I, Chen BE, Anderson WF et al.: Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J. Clin. Oncol. 25, 1683-1690 (2007).
35. Moon RC, Thompson HJ, Becci PJ et al.: N-(4-Hydroxyphenyl)retinamide a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39 1339-1346 (1979).
36. Veronesi U, De Palo G, Marubini E et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl Cancer Inst. 91 1847-1856 (1999).
37. Veronesi U, Mariani L, Decensi A et al.: Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17 1065-1071 (2006).
38. Fisher B, Bryant J, Wolmark N et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16, 2672-2685 (1998).
39. Wolmark N, Wang J, Mamounas E et al.: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. 30, 96-102 (2001).
40. Jatoi I, Becher H, Leake CR: Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer 98, 894-899 (2003).
41. Jatoi I, Anderson WF, Rao SR et al.: Breast cancer trends among black and white women in the United States. J. Clin. Oncol. 23, 7836-7841 (2005).
42. Menashe I, Anderson WF, Jatoi I et al.: Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J. Natl Cancer Inst. 101, 993-1000 (2009).
43. Anderson WF, Rosenberg PS, Menashe I et al.: Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J. Natl Cancer Inst. 100, 1804-1814 (2008).
44. Baines CJ: Mammography screening: are women really giving informed consent? J. Natl Cancer Inst. 95, 1508-1511 (2003).
45. Dignam JJ: Effcacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J. Natl Cancer Inst. Monogr. 30, 36-43 (2001).
46. Jatoi I, Hilsenbeck SG, Clark GM et al.: Signifcance of axillary lymph node metastasis in primary breast cancer. J. Clin. Oncol. 17, 2334-2340 (1999).
47. Shipitsin M, Campbell LL, Argani P et al.: Molecular defnition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (2007).
48. Fan C, Oh DS, Wessels L et al.: Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).